Mannitolo Fresenius Kabi Italia (Mannitol)

Mannitol works by increasing plasma osmolarity, which draws water from cells and interstitial spaces into the bloodstream. This osmotic shift reduces swelling in the brain and eyes, expands intravascular volume, and creates an osmotic diuretic effect that enhances urine output.

The dose of Mannitolo Fresenius Kabi Italia is determined by the prescribing clinician based on the specific indication, patient weight, renal function, and clinical response. No fixed regimen is provided here; the prescriber sets the appropriate infusion rate and total amount.

Safety data for mannitol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Mannitol is the most widely used osmotic diuretic due to its rapid onset, predictable pharmacokinetics, and dual ability to lower intracranial pressure and increase urine output. Other agents, such as hypertonic saline, may be used in specific scenarios but generally lack the same versatility and extensive safety profile of mannitol.

Mannitolo should be stored refrigerated at 2‑8 °C, protected from light, and never frozen. The vial must be kept in its original packaging to maintain sterility and should be gently inverted to mix if any sediment is observed; shaking is not recommended.

Mannitolo is administered intravenously, typically as a slow infusion. The exact rate and total volume are prescribed by the clinician, who may adjust based on the patient’s hemodynamic status, renal function, and therapeutic response.

Serious risks include pulmonary edema from fluid overload, severe electrolyte disturbances (especially hyponatremia or hypokalemia), acute renal failure in susceptible individuals, and rare anaphylactic reactions. Continuous monitoring of fluid balance and electrolytes is essential during therapy.

Mannitolo is contraindicated in patients with known hypersensitivity to mannitol, severe renal insufficiency where diuresis is ineffective, active pulmonary edema, and uncontrolled heart failure where rapid volume expansion could be harmful.